# A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct06389292/  
OnCo record `nct06389292` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Azacitidine in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT06389292 by Ascentage Pharma Group Inc., with 486 participants planned, started 2024-06-11 and due to reach its primary completion in 2028-05-25. Interventions recorded: APG-2575(Lisaftoclax ) and Azacitidine Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06389292
- Phase: 3
- Setting: A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (GLORA-3)
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 486

## Sources

- ClinicalTrials.gov NCT06389292: https://clinicaltrials.gov/study/NCT06389292

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06389292.json